Bio-Path (BPTH) Short Interest Ratio & Short Volume → Biden replacement revealed? (From Paradigm Press) (Ad) Free BPTH Stock Alerts $2.73 +0.07 (+2.63%) (As of 11:59 AM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Bio-Path Short Interest DataCurrent Short Volume27,400 sharesPrevious Short Volume67,400 sharesChange Vs. Previous Month-59.35%Dollar Volume Sold Short$80,830.00Short Interest Ratio / Days to Cover0.0Last Record DateApril 15, 2024Outstanding Shares680,000 sharesFloat Size752,100 sharesShort Percent of Float3.64%Today's Trading Volume190,077 sharesAverage Trading Volume1,048,947 sharesToday's Volume Vs. Average18% Short Selling Bio-Path ? Sign up to receive the latest short interest report for Bio-Path and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBPTH Short Interest Over TimeBPTH Days to Cover Over TimeBPTH Percentage of Float Shorted Over Time Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report Bio-Path Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202427,400 shares $80,830.00 -59.4%3.6%0 $2.95 3/31/202467,400 shares $277,688.00 +6.3%9.0%2.7 $4.12 3/15/202463,400 shares $291,640.00 +284.2%9.6%3 $4.60 2/29/202416,500 shares $100,320.00 -14.5%2.7%1.7 $6.08 2/15/202419,300 shares $170,612.00 -94.9%3.1%2.9 $8.84 1/31/2024378,300 shares $162,669.00 -6.0%N/A3.5 $0.43 Get the Latest News and Ratings for BPTH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024402,500 shares $201,250.00 +7.3%N/A1.7 $0.50 12/31/2023375,200 shares $173,717.60 -12.9%N/A0.1 $0.46 12/15/2023430,900 shares $202,523.00 -18.6%N/A0.2 $0.47 11/30/2023529,600 shares $296,576.00 -23.9%N/A0.2 $0.56 11/15/2023695,700 shares $371,225.52 -28.3%N/A0.3 $0.53 10/31/2023969,600 shares $639,451.20 +240.3%N/A0.4 $0.66 10/15/2023284,900 shares $213,675.00 +66.9%N/A0.1 $0.75 9/30/2023170,700 shares $63,159.00 -21.2%N/A0.5 $0.37 9/15/2023216,700 shares $88,847.00 +23.1%N/A0.6 $0.41 8/31/2023176,000 shares $72,652.80 -19.4%N/A0.5 $0.41 8/15/2023218,300 shares $82,735.70 -46.7%N/A0.7 $0.38 7/31/2023409,300 shares $433,858.00 +44.1%N/A1.4 $1.06 7/15/2023284,000 shares $369,200.00 +44.8%N/A6.9 $1.30 6/30/2023196,200 shares $349,236.00 +111.9%N/A5.8 $1.78 6/15/202392,600 shares $152,780.74 +15.3%N/A2.8 $1.65 5/31/202380,300 shares $132,495.00 +7.5%N/A3 $1.65 5/15/202374,700 shares $112,050.00 +6.1%N/A2.5 $1.50 4/30/202370,400 shares $99,264.00 -15.8%N/A2.3 $1.41 4/15/202383,600 shares $116,195.64 +10.0%N/A2.4 $1.39 3/31/202376,000 shares $105,640.00 +18.6%N/A2.1 $1.39 3/15/202364,100 shares $96,150.00 -9.7%N/A1.7 $1.50 2/28/202371,000 shares $128,510.00 +59.2%N/A1.8 $1.81 2/15/202344,600 shares $88,018.10 +49.7%N/A1.1 $1.97 1/31/202329,800 shares $61,984.00 +122.4%N/A0.4 $2.08 1/15/202313,400 shares $23,986.00 -53.2%N/A0.2 $1.79 12/30/202228,600 shares $43,186.00 -21.6%N/A0.5 $1.51 12/15/202236,500 shares $54,385.00 +644.9%N/A0.6 $1.49 11/30/20224,900 shares $7,203.00 -84.9%N/A0.1 $1.47 11/15/202232,500 shares $49,725.00 -5.3%N/A0.6 $1.53 10/31/202234,300 shares $111,475.00 +0.3%2.0%0.8 $3.25 10/15/202234,200 shares $110,466.00 -0.9%2.0%2 $3.23 9/30/202234,500 shares $110,055.00 -7.0%2.0%1.7 $3.19 9/15/202237,100 shares $139,867.00 -13.3%2.2%1.3 $3.77 8/31/202242,800 shares $156,648.00 -11.0%2.5%1.4 $3.66Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. BPTH Short Interest - Frequently Asked Questions What is Bio-Path's current short interest? Short interest is the volume of Bio-Path shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 27,400 shares of BPTH short. 3.64% of Bio-Path's shares are currently sold short. Learn More on Bio-Path's current short interest. Which institutional investors are shorting Bio-Path? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Bio-Path: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Bio-Path? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.64% of Bio-Path's floating shares are currently sold short. Is Bio-Path's short interest increasing or decreasing? Bio-Path saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 27,400 shares, a decline of 59.3% from the previous total of 67,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Bio-Path's float size? Bio-Path currently has issued a total of 680,000 shares. Some of Bio-Path's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Bio-Path currently has a public float of 752,100 shares. How does Bio-Path's short interest compare to its competitors? 3.64% of Bio-Path's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Bio-Path: Biodexa Pharmaceuticals Plc (14.70%), Qualigen Therapeutics, Inc. (0.91%), PainReform Ltd. (2.95%), Clearmind Medicine Inc. (5.49%), 180 Life Sciences Corp. (3.30%), Notable Labs, Ltd. (0.02%), Galmed Pharmaceuticals Ltd. (2.21%), Dermata Therapeutics, Inc. (1.24%), InMed Pharmaceuticals Inc. (1.89%), CNS Pharmaceuticals, Inc. (0.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Bio-Path stock? Short selling BPTH is an investing strategy that aims to generate trading profit from Bio-Path as its price is falling. BPTH shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Bio-Path? A short squeeze for Bio-Path occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BPTH, which in turn drives the price of the stock up even further. How often is Bio-Path's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BPTH, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: BDRX Short Squeeze QLGN Short Squeeze PRFX Short Squeeze CMND Short Squeeze ATNF Short Squeeze NTBL Short Squeeze GLMD Short Squeeze DRMA Short Squeeze INM Short Squeeze CNSP Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BPTH) was last updated on 5/3/2024 by MarketBeat.com Staff From Our Partners[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe AI stock to buy right nowStockEarningsUrgent Nvidia WarningAltimetryBiden Nomination CANCELED?The Freeport SocietyCould Your Accounts Be Frozen?Allegiance GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace